Eads & Heald Wealth Management Sells 3,383 Shares of CVS Health Co. (NYSE:CVS)

Eads & Heald Wealth Management reduced its holdings in CVS Health Co. (NYSE:CVS) by 23.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,251 shares of the pharmacy operator’s stock after selling 3,383 shares during the quarter. Eads & Heald Wealth Management’s holdings in CVS Health were worth $505,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in CVS. Perfromance Wealth Partners LLC acquired a new position in shares of CVS Health during the 4th quarter valued at $475,000. Fort Washington Investment Advisors Inc. OH raised its holdings in shares of CVS Health by 17.6% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,089,654 shares of the pharmacy operator’s stock valued at $48,915,000 after purchasing an additional 163,148 shares during the period. Ballentine Partners LLC boosted its position in shares of CVS Health by 17.5% during the 4th quarter. Ballentine Partners LLC now owns 5,314 shares of the pharmacy operator’s stock worth $239,000 after purchasing an additional 793 shares in the last quarter. LaFleur & Godfrey LLC grew its stake in shares of CVS Health by 49.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator’s stock valued at $217,000 after buying an additional 1,610 shares during the period. Finally, AHL Investment Management Inc. increased its position in CVS Health by 1.7% in the 4th quarter. AHL Investment Management Inc. now owns 43,316 shares of the pharmacy operator’s stock valued at $1,944,000 after buying an additional 713 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Performance

NYSE CVS opened at $53.14 on Wednesday. The company has a market capitalization of $66.87 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 0.79 and a beta of 0.59. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a 50-day simple moving average of $51.27 and a 200 day simple moving average of $56.29.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. During the same quarter in the previous year, the firm posted $2.21 EPS. CVS Health’s revenue was up 6.3% on a year-over-year basis. On average, research analysts predict that CVS Health Co. will post 5.22 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 5.01%. The ex-dividend date of this dividend is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 67.51%.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent research reports. StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. UBS Group lifted their price target on shares of CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $62.00 price objective on shares of CVS Health in a report on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a report on Tuesday, December 3rd. Finally, Barclays lowered their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.71.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.